The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: Accumulated evidence from randomised controlled trial

International Journal of Clinical Practice

Volumn 70, Issue 2, 2016, Pages 132-141

  Zhou, J B ^a   Bai, L ^b   Wang, Y ^a   Yang, J K ^a,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Haidian Hospital   (China)

^c Beijing Key Laboratory of Diabetes Research and Care   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; ASTHENIA; BRONCHITIS; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; BODY WEIGHT; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS;

EID: 84957430702     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12761     Document Type: Article

References (21)

1. Unger RH, Orci L,. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975; 1: 14-6.
2. Szoke E, Shrayyef MZ, Messing S, et al., Effect of aging on glucose homeostasis: accelerated deterioration of beta-cell function in individuals with impaired glucose tolerance. Diabetes Care 2008; 31: 539-43.
3. Solis-Herrera C, Triplitt C, Garduno-GarciaJde J, etal. Mechanisms of glucose lowering of dipeptidylpeptidase-4 inhibitor sitagliptin when used alone or with metforminin type 2 diabetes: a double-tracer study. Diabetes Care 2013; 36: 2756-62.
4. Vella A,. Mechanism of action of DPP-4 inhibitors: new insights. J Clin Endocrinol Metab 2012; 97: 2626-8.
5. Nathan DM, Buse JB, Davidson MB, et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care 2009; 32: 193-203.
6. Gerich J,. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010; 90: 131-40.
7. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL,. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; 2: CD006739.
8. Amori RE, Lau J, Pittas AG,. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
9. Higgins JPT, Deeks JJ,. Selecting studies and collecting data. In:, Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Cochrane Collaboration, 2011.
10. Davey SG, Egger M,. Meta-analyses of randomised controlled trials. Lancet 1997; 350: 1182.
11. Egger M, Davey SG, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
12. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
13. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
14. Defronzo RA,. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95.
15. Farngren J, Persson M, Schweizer A, et al., Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counter regulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 2012; 97: 3799-806.
16. Unger RH, Cherrington AD,. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012; 122: 4-12.
17. Ahren B, Foley JE,. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract 2008; 62 (Suppl. 159): 8-14.
18. Pratley RE,. Expanding treatment options for type 2 diabetes: the old and the new. Diabetes Educ 2009; 35 (Suppl. 1): 4S-11S.
19. Monami M, Iacomelli I, Marchionni N, Mannucci E,. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20: 224-35.
20. Gat-Yablonski G, Shalitin S, Phillip M,. Maturity onset diabetes of the young-review. Pediatr Endocrinol Rev 2006; 3 (Suppl. 3): 514-20.
21. Pearson ER, Donnelly LA, Kimber C, et al., Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56: 2178-82.